argenx
- Country
- ๐ง๐ชBelgium
- Ownership
- -
- Established
- 2008-01-01
- Employees
- -
- Market Cap
- $31.2B
- Website
- https://www.argenx.com/
Efgartigimod Expanded Access for Generalized Myasthenia Gravis
- Conditions
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- argenx
- Registration Number
- NCT04777734
- Locations
- ๐บ๐ธ
Investigator site 12 - Approved for Marketing, Chicago, Illinois, United States
๐บ๐ธInvestigator Site 6 - Approved for Marketing, New Hyde Park, New York, United States
๐บ๐ธInvestigator site 2 - Approved for Marketing, Henrico, Virginia, United States
Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis
- Conditions
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- argenx
- Target Recruit Count
- 110
- Registration Number
- NCT04735432
- Locations
- ๐บ๐ธ
Investigator site 2 - US0010108, Boca Raton, Florida, United States
๐บ๐ธInvestigator Site 43 - 0010019, Cleveland, Ohio, United States
๐ต๐ฑInvestigator Site 22 - PL0480005, Krakรณw, Poland
A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- argenx
- Target Recruit Count
- 207
- Registration Number
- NCT04687072
- Locations
- ๐บ๐ธ
Investigator site 0010036, Los Angeles, California, United States
๐บ๐ธInvestigator site 0010040, Columbus, Ohio, United States
๐บ๐ธInvestigator Site 0010115, Pittsburgh, Pennsylvania, United States
A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
- Conditions
- Interventions
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- argenx
- Target Recruit Count
- 222
- Registration Number
- NCT04598451
- Locations
- ๐ฌ๐ง
Investigator site 117 - UK0440021, Birmingham, United Kingdom
๐ง๐ฌInvestigator site 30 - BG350012, Pleven, Bulgaria
๐ง๐ฌInvestigator site 31 - BG3590013, Plovdiv, Bulgaria
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
- Conditions
- Interventions
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- argenx
- Target Recruit Count
- 183
- Registration Number
- NCT04598477
- Locations
- ๐บ๐ธ
Investigator site 124 - US0010092, Redwood City, California, United States
๐บ๐ธInvestigator site 1 - US0010087, Boca Raton, Florida, United States
๐บ๐ธInvestigator site 91 - US0010109, Orlando, Florida, United States
A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2021-04-05
- Lead Sponsor
- argenx
- Target Recruit Count
- 54
- Registration Number
- NCT04564066
- Locations
- ๐ณ๐ฑ
Study Site 1, Groningen, Netherlands
SAD and MAD Study With IV and SC Doses of ARGX-117
- Conditions
- Interventions
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- argenx
- Target Recruit Count
- 110
- Registration Number
- NCT04532125
- Locations
- ๐ณ๐ฑ
Investigator Site 1, Groningen, Netherlands
A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
- Conditions
- Interventions
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- argenx
- Target Recruit Count
- 322
- Registration Number
- NCT04281472
- Locations
- ๐บ๐ธ
Investigator site 0010077, Durham, North Carolina, United States
๐จ๐ณInvestigator site 0860038, Fuzhou, China
๐จ๐ณInvestigator site 0860031, Jinan, China
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
- Conditions
- Interventions
- First Posted Date
- 2020-02-21
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- argenx
- Target Recruit Count
- 229
- Registration Number
- NCT04280718
- Locations
- ๐ท๐บ
Investigator site 0070021, Saransk, Russian Federation
๐บ๐ฆInvestigator Site 3800010, Ivano-Frankivs'k, Ukraine
๐จ๐ณInvestigator site 0860036, Chengdu, China
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)
- Conditions
- Interventions
- First Posted Date
- 2020-02-18
- Last Posted Date
- 2020-09-14
- Lead Sponsor
- argenx
- Registration Number
- NCT04274452